Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - December 2013


Advances in Electrophysiology Europe, 2013 – A Spotlight on Ion Channel Research – Highlighting Automated Physiology

10 Dec 2013 - 10 Dec 2013 - Saffron Walden, Cambridge, UK



Bookmark and Share


Advances in drug discovery technologies now allow ion channels to be significantly more promising targets for drug discovery. This meeting has been structured to focus on recent developments in patch clamp, which have revolutionised the use of electrophysiology as a tool for drug discovery and functional screening. An authoritative panel of experienced pharmaceutical industry scientists and academics has been assembled for this meeting that will have a special emphasis upon automated electrophysiology.

Professor David Brown, UCL, UK and Dr Edward Stevens, Pfizer Neusentis, UK will give the keynote presentations. Professor David Brown will discuss his far-reaching research into the regulation of ion channels that control neural excitability, with a special emphasis on his work with the Kv7 potassium channel. Drawing upon his extensive knowledge of the drug discovery industry both in CRO’s and pharmaceutical companies, Dr Edward Stevens will review the contribution that automated electrophysiology is making to drug discovery and development.

Speakers will then discuss the development and potential of these new technologies, present experimental results obtained with these systems and debate the potential impact of current technologies and future developments.

These presentations will include data from platforms including the IonWorks Barracuda®, IonWorks® Quattro™, PatchXpress® and IonFlux™ instrumentation:

  • Matthew Bridgland-Taylor, AstraZeneca, UK - Exploitation of the IonWorks Barracuda Automated Electrophysiology Platform to Improve Assessment of Cardiac Liability
  • Kelly Gatfield, GlaxoSmithKline, UK - Development of IonWorks Barracuda assays for use in early stage safety profiling
  • Gary Clarke, BioFocus DPI, UK - Ion Channel Drug Discovery: Case Study Utilising Automated Electrophysiology
  • Mark McPate, Novartis, UK - Investigation of the TRPC Channel using the IonWorks Quattro
  • Oliver Leven, GeneData, Switzerland - Genedata Screener for Automated Patch Clamping



Further information
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!